EUVIMEDSkopri EUVIMED
Kommentar

Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B

Xingfei Pan, Liyang Zhou, Jing Hu, Panpan Zhai, Xueting Ou, Fang He, Calvin Q Pan iD

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70173 ↗

At a glance

Kommentar in Alimentary Pharmacology & Therapeutics, 2025. Written by Xingfei Pan and 6 co-authors. Institution: Department of Infectious Diseases, Guangdong Provincial Key Laboratory of Major Obstetric Diseases; Guangdong Provincial Clinical Research Center for…. Major MEDLINE topics: Hepatitis B, Chronic, Pregnancy Complications, Infectious, Tenofovir, Antiviral Agents. Cited 7 times so far (Crossref); 26 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Mothers with chronic hepatitis B and advanced fibrosis may require antiviral therapy throughout pregnancy. Current guidelines recommend tenofovir disoproxil fumarate (TDF), which is unsuitable for mothers at risk of renal dysfunction or decreased bone mineral density.

Aims

This study aimed to evaluate the safety of tenofovir alafenamide (TAF) therapy during pregnancy.

Methods

Mothers with chronic hepatitis B treated with TAF or no therapy were retrospectively enrolled and categorised into three groups: (A) TAF‐first trimester, (B) TAF‐late trimester and (C) no treatment. Propensity score matching was applied to create comparable groups. Primary assessments included serious adverse events up to postpartum week 28, while secondary assessments examined predictors of such events and vertical transmission rates.

Results

Among 284 mothers, 160 were selected. No significant differences were observed in foetal loss, low birth weight, preterm delivery or congenital abnormalities between groups A and B, or between groups A and C. Other adverse events were similar across groups, except for a higher incidence of gestational diabetes in the TAF‐first trimester group. In vitro fertilisation was identified as the sole predictor of serious events. No infants were reported with hepatitis B virus infection at 28 weeks postpartum.

Conclusions

This study suggests that TAF treatment throughout pregnancy is safe for mothers with chronic hepatitis B and their infants. TAF therapy represents a viable treatment option for these mothers.

Subjects

MeSH terms (MEDLINE)

Hepatitis B, ChronicPregnancy Complications, InfectiousTenofovirAntiviral AgentsInfectious Disease Transmission, VerticalAdenineHumansFemalePregnancyAdultRetrospective StudiesAlaninePregnancy OutcomeYoung AdultInfant, Newborn

Author keywords

TAF safetyadverse pregnancy outcomesfoetal exposure to TAFmaternal HBV infectionpreconception antiviral treatment

Substances

tenofovir alafenamideTenofovirAntiviral AgentsAlanineAdenine

Authors and institutions

  • Department of Infectious Diseases, Guangdong Provincial Key Laboratory of Major Obstetric Diseases; Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou M…
  • Department of Obstetrics and Gynecology, Department of Obstetrics, Guangdong Provincial Key Laboratory of Major Obstetric Diseases; Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology; Guangdong-…
  • Department of Obstetrics and Gynecology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases; Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology; Guangdong-Hong Kong-Macao Greater Ba…
  • Guangzhou Medical University, Guangzhou, China.
  • Division of Gastroenterology and Hepatology, Department of Medicine, NYU Langone Health, NYU Grossman School of Medicine, New York, USA.

ORCID profiles: Calvin Q Pan

Cite

APA

Pan, X., Zhou, L., Hu, J., Zhai, P., Ou, X., He, F., & Pan, C. Q. (2025). Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70173

Vancouver

Pan X, Zhou L, Hu J, Zhai P, Ou X, He F, et al. Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70173

BibTeX
@article{Pan2025,
  author = {Pan, Xingfei and Zhou, Liyang and Hu, Jing and Zhai, Panpan and Ou, Xueting and He, Fang and Pan, Calvin Q},
  title = {Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70173}
}
Start for free →